{"public_id":"co_b87617beade29d4fca97a28c5b7c9ce8","status":"active","merged_into_public_id":null,"resolved_public_id":"co_b87617beade29d4fca97a28c5b7c9ce8","name":"lamivudine","description":"An oral nucleoside analogue evaluated as a treatment for chronic hepatitis B.","aliases":[],"types":["drug"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":35926507,"title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","citation_count":1570,"url":"https://sah.borca.ai/papers/35926507"}],"claims":[{"public_id":"cl_352809ee672af558cd4f030d611e2127","text":"The 100 mg daily dose was more effective than the 25 mg daily dose.","corpus_id":35926507,"url":"https://sah.borca.ai/claims/cl_352809ee672af558cd4f030d611e2127"},{"public_id":"cl_472f4d210c4c3db2802ee3b8bf08cf14","text":"A reduction of at least two points in the Knodell necroinflammatory score occurred in 56% of patients receiving 100 mg lamivudine, 49% receiving 25 mg, and 25% receiving placebo.","corpus_id":35926507,"url":"https://sah.borca.ai/claims/cl_472f4d210c4c3db2802ee3b8bf08cf14"},{"public_id":"cl_9a14f48c16fa4a3a5c39ff232222ab5a","text":"Lamivudine produced substantial histologic improvement in many patients with chronic hepatitis B over one year.","corpus_id":35926507,"url":"https://sah.borca.ai/claims/cl_9a14f48c16fa4a3a5c39ff232222ab5a"},{"public_id":"cl_d77c0095b5f07487b3c0d4ce330968d0","text":"Adverse events were similar across treatment groups, with few serious events.","corpus_id":35926507,"url":"https://sah.borca.ai/claims/cl_d77c0095b5f07487b3c0d4ce330968d0"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_b87617beade29d4fca97a28c5b7c9ce8","url":"https://sah.borca.ai/concepts/co_b87617beade29d4fca97a28c5b7c9ce8"}